Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2026-03-16 Proxy Solicitation & In…
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of an upcoming Annual General Meeting (AGM) for Cha Biotech. It details the date, location, agenda items (such as financial statement approval, board appointments, and bylaw changes), and voting procedures. This document is a standard 'Notice of Meeting' or 'Proxy Statement' type filing, which falls under the Proxy Solicitation & Information Statement category as it provides shareholders with the necessary information to vote on upcoming resolutions.
2026-03-16 Korean
타법인주식및출자증권처분결정(자율공시)
M&A Activity Classification · 95% confidence The document is a regulatory filing regarding the disposal of shares in another company (Solidus Investment) by Cha Biotech. This is a corporate action involving the divestment of a subsidiary, which falls under M&A activity or corporate restructuring. Given the specific nature of the 'Disposal of shares and equity securities of other corporations' (타법인주식및출자증권처분결정), it is classified as M&A Activity (TAR).
2026-03-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the shareholding status, changes in ownership, and special relationships of major shareholders (Cha Kwang-yul and related parties) in Cha Biotech. This falls under the category of Major Shareholding Notification.
2026-03-11 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the shareholding status, changes in ownership, and special relationships of the major shareholder (Cha Kwang-yul) and related parties in the company 'Cha Biotech'. This document type is specifically used to notify the financial authorities of significant changes in share ownership, which falls under the 'Major Shareholding Notification' category.
2026-03-05 Korean
주요사항보고서(제3자의전환사채매수선택권행사)
Regulatory Filings Classification · 95% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Services Commission in South Korea. It details the exercise of a call option (매수선택권) on convertible bonds by a third party (Meritz Securities). This type of regulatory filing regarding capital structure changes, specifically the exercise of options related to convertible debt, falls under the category of 'Regulatory Filings' (RNS) as it is a specific corporate disclosure required by Korean financial regulations that does not fit into the other specialized categories like M&A or Share Issues.
2026-03-05 Korean
주요사항보고서(제3자의신주인수권부사채매수선택권행사)
Regulatory Filings Classification · 95% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Supervisory Service of South Korea. It details the exercise of a call option (매수선택권) on a Bond with Warrant (BW) by a third party (Meritz Securities). This type of filing, which reports specific corporate actions regarding capital structure and financial instruments, falls under the category of regulatory filings for miscellaneous corporate events that do not fit into standard financial reporting categories like 10-K or IR.
2026-03-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.